All News
Filter:
18.05.2022
press release
MorphoSys AG Reports Outcome of Annual General Meeting 2022
PDF
12.05.2022
press release
MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
PDF
04.05.2022
press release
MorphoSys AG Reports First Quarter 2022 Financial Results
PDF
28.04.2022
press release
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
PDF
22.03.2022
press release
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
PDF
16.03.2022
press release
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
PDF
15.03.2022
press release
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
PDF
10.03.2022
press release
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
PDF
10.03.2022
adhoc
Ad hoc: MorphoSys AG reports non-cash impairment charge of € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021
PDF
24.01.2022
press release
MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
PDF